A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Series of Transplantable Patient-Derived Xenograft Models for Acute Myeloid Leukemia Subgroups Lacking Established Cell Lines

  • By

  • Binje Vick

  • Vindi Jurinovic

  • Kristina Kuhbandner

  • Lena Lagally

  • Lisa Latzko

  • Chiara Arnreich

  • Gerulf Hänel

  • Amelie Muth

  • Maximilian Schönung

  • Arnold Kloos

  • Maja Rothenberg-Thurley

  • Annika M. Dufour

  • Stephanie Schneider

  • Lesca M. Holdt

  • Liliana Mura

  • Fabian Klein

  • Annette Frank

  • Dhruv Mehra

  • Annika Fröhlich

  • Johannes W. Bagnoli

  • Maya C. André

  • Claudia D. Baldus

  • Martin Carroll

  • Christine Dierks

  • Martin Ebinger

  • Katharina S. Götze

  • Pablo Menéndez

  • Christian Récher

  • Ambrine Sahal

  • Jean-Emmanuel Sarry

  • Christian Thiede

  • Talía Velasco-Hernández

  • Xiaoyan Wei

  • Jan H. Klusmann

  • Wolfgang Enard

  • Michael von Bergwelt-Baildon

  • Wolfgang Hiddemann

  • Klaus H. Metzeler

  • Philipp A. Greif

  • Michael Heuser

  • Daniel B. Lipka

  • Marion Subklewe

  • Sebastian Vosberg

  • Tobias Herold

  • Karsten Spiekermann

  • Irmela Jeremias

  • October 5, 2026

Share

Clinical Scorecard: A Series of Transplantable Patient-Derived Xenograft Models for Acute Myeloid Leukemia Subgroups Lacking Established Cell Lines

At a Glance

CategoryDetail
ConditionAcute Myeloid Leukemia (AML)
Key MechanismsClonal expansion of immature myeloid cells, therapy resistance, and interactions with the bone marrow niche.
Target PopulationPatients with acute myeloid leukemia, particularly those lacking established cell lines.
Care SettingCancer research and pre-clinical investigations.

Key Highlights

  • Development of serially transplantable patient-derived xenograft (PDX) models for AML.
  • PDX models improve understanding of disease pathogenesis and therapy resistance.
  • Models facilitate pre-clinical investigations and novel therapeutic strategies.

Guideline-Based Recommendations

Diagnosis

  • Utilize patient-derived xenograft models to study AML subgroups.

Management

  • Conduct phase II-like and long-term treatment trials using PDX models.

Monitoring & Follow-up

  • Monitor tumor burden using in vivo bioluminescence imaging.

Risks

  • Limited access to primary patient material may constrain model availability.

Patient & Prescribing Data

Patients with acute myeloid leukemia, especially those with limited treatment options.

Cytarabine and DaunoXome used in repetitive treatment cycles in PDX models.

Clinical Best Practices

  • Ensure ethical animal use in research.
  • Record all procedures and values systematically.
  • Avoid pre-irradiation of mice before cell administration to prevent bias.

Related Resources & Content

Original Source(s)

A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist

  • by Binje Vick, Vindi Jurinovic, Kristina Kuhbandner, Lena Lagally, Lisa Latzko, Chiara Arnreich, Gerulf Hänel, Amelie Muth, Maximilian Schönung, Arnold Kloos, Maja Rothenberg-Thurley, Annika M. Dufour, Stephanie Schneider, Lesca M. Holdt, Liliana Mura, Fabian Klein, Annette Frank, Dhruv Mehra, Annika Fröhlich, Johannes W. Bagnoli, Maya C. André, Claudia D. Baldus, Martin Carroll, Christine Dierks, Martin Ebinger, Katharina S. Götze, Pablo Menéndez, Christian Récher, Ambrine Sahal, Jean-Emmanuel Sarry, Christian Thiede, Talía Velasco-Hernández, Xiaoyan Wei, Jan H. Klusmann, Wolfgang Enard, Michael von Bergwelt-Baildon, Wolfgang Hiddemann, Klaus H. Metzeler, Philipp A. Greif, Michael Heuser, Daniel B. Lipka, Marion Subklewe, Sebastian Vosberg, Tobias Herold, Karsten Spiekermann, Irmela Jeremias

  • October 5, 2026

Related Content

The Keys to Opening Access to Clinical Trials

Same-Patient, Same–Time Point Evidence for Radiomics Benchmarking

Overall Survival Benefit and Long-Term Safety of Romiplostim in Persistent Chemotherapy-Induced Thrombocytopenia